Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6HXTS)

• Drug Name: Anamorelin Drug Info
• Synonyms: 249921-19-5; UNII-DD5RBA1NKF; DD5RBA1NKF; RC 1291; Anamorelin [INN]; ONO-7643; SCHEMBL935751; CHEMBL2110579; EX-A154; DTXSID20179702; C31H42N6O3; BCP06108; 3444AH; ZINC43130908; AKOS030526752; SB16911; API0008642; RC-1291; NCGC00378854-01; KB-80338; HY-14734; BC600755; (3R)-1-(2-Methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide; AB0165721; FT-0773543; W-5500; 921A195; CS 1036

Indication

Disease Entry	ICD 11	Status	REF
Carbohydrate metabolism disorder	5C51.Z	Phase 3	[1]

• Cross-matching ID:
  PubChem CID: 9828911
  CAS Number: CAS 249921-19-5
  TTD Drug ID: DM6HXTS

Molecule-Related Drug Atlas

Drug(s) Targeting Growth hormone secretagogue receptor 1 (GHSR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GHRP-2	DMKGH0R	Growth hormone deficiency	5A61.3	Approved	[4]
Ibutamoren	DMFJ8LT	Fibromyalgia	MG30.01	Approved	[5]
Macimorelin	DMQYJIR	Growth hormone deficiency	5A61.3	Approved	[6]
TZP-101	DMOE582	Gastrointestinal disease	DE2Z	Phase 2b	[7]
GTP-200	DM03NQS	Solid tumour/cancer	2A00-2F9Z	Phase 2	[8]
RQ-00000005	DMBHN4K	Frailty	MG2A	Phase 2	[9]
Tabimorelin	DMNL9HO	Growth hormone deficiency	5A61.3	Phase 2	[10]
Ibutamoren mesylate	DMN2CM0	Growth hormone deficiency	5A61.3	Phase 2	[11]
Ipamorelin	DM9PJZT	Postoperative ileus	DA91-DB30	Phase 1/2	[12]
PF-05190457	DM7B2JC	Type-2 diabetes	5A11	Phase 1	[13]

Drug(s) Targeting Alpha-glucosidase (GLA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cipaglucosidase alfa	DMAPDH2	Glycogen storage disease type II	5C51.3	Approved in EU	[14]
Cipaglucosidase alfa	DMAPDH2	Glycogen storage disease type II	5C51.3	Approved in EU	[15]
Deoxynojirimycin	DM2ATZB	Pompe disease	5C51.3	Phase 3	[16]
Maltose	DMH0ROP	N. A.	N. A.	Phase 1/2	[17]
AAV2/8-LSPhGAA	DMIX5HF	Pompe disease	5C51.3	Phase 1	[18]
Nicotinamide-Adenine-Dinucleotide	DM9LRKB	N. A.	N. A.	Investigative	[19]
Beta-D-Glucose	DM5IHYP	Discovery agent	N.A.	Investigative	[19]
Double Oxidized Cysteine	DM6TU84	Discovery agent	N.A.	Investigative	[19]
POP-1	DMVTKCX	Solid tumour/cancer	2A00-2F9Z	Investigative	[20]
JBP-1	DM0KMPN	Solid tumour/cancer	2A00-2F9Z	Investigative	[20]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Alpha-glucosidase (GLA)	TTHCF4J	LYAG_HUMAN; GANAB_HUMAN; GANC_HUMAN	Modulator	[2]
Growth hormone secretagogue receptor 1 (GHSR)	TTWDC17	GHSR_HUMAN	Stimulator	[3]

References

• [1] ClinicalTrials.gov (NCT01395914) Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3). U.S. National Institutes of Health.
• [2] Absorption, elimination, and metabolism of CS-1036, a novel -amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.Drug Metab Dispos.2013 Apr;41(4):878-87.
• [3] Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers. Growth Horm IGF Res. 2009 Jun;19(3):267-73.
• [4] GH-releasing peptide-2 increases fat mass in mice lacking NPY: indication for a crucial mediating role of hypothalamic agouti-related protein. Endocrinology. 2002 Feb;143(2):558-68.
• [5] Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):7001-5.
• [6] National Cancer Institute Drug Dictionary (drug id 735530).
• [7] Contribution of protein binding to the pharmacokinetics of the ghrelin receptor agonist TZP-101 in healthy volunteers and adults with symptomatic gastroparesis: two randomized, double-blind studies and a binding profile study. Clin Drug Investig. 2009;29(6):409-18.
• [8] Orphan GPCR research. Br J Pharmacol. 2008 March; 153(Suppl 1): S339-S346.
• [9] Hypotensive effects of ghrelin receptor agonists mediated through a novel receptor. Br J Pharmacol. 2014 Mar;171(5):1275-86.
• [10] Pharmacological characterisation of a new oral GH secretagogue, NN703. Eur J Endocrinol. 1999 Aug;141(2):180-9.
• [11] Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children. Clin Pharmacol Ther. 2001 Jul;70(1):91-8.
• [12] Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus.J Pharmacol Exp Ther.2009 Jun;329(3):1110-6.
• [13] A gift for research. SciBX 7(6); doi:10.1038/scibx.2014.160. Feb. 13 2014
• [14] Cipaglucosidase Alfa: First Approval. Drugs. 2023 Jun;83(8):739-745.
• [15] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761204
• [16] Nitrogen-in-the-ring pyranoses and furanoses: structural basis of inhibition of mammalian glycosidases. J Med Chem. 1994 Oct 28;37(22):3701-6.
• [17] DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
• [18] ClinicalTrials.gov (NCT03533673) AAV2/8-LSPhGAA in Late-Onset Pompe Disease. U.S. National Institutes of Health.
• [19] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [20] US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT.